Johnson & Johnson third-quarter sales miss mark, hurt by strong dollar

Johnson & Johnson reported third-quarter sales well below Wall Street estimates, hurt by the stronger dollar and disappointing demand for its Remicade arthritis drug and its Xarelto blood clot preventer. J&J shares fell 0.7 percent, even though the company also said on Tuesday it planned to buy back up to $10 billion (7 billion pound) worth of its common stock.. The repurchases, to be financed with debt and to have no time limit, would remove about 3.8 percent of the company's outstandin